Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
• Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention.
Gespeichert in:
| Autor*in: |
Severe, Brooke [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Statistical analysis to identify biomarkers for safety - Clark, Matthew ELSEVIER, 2018, an international journal on biomedical and psychosocial approaches, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:213 ; year:2020 ; day:1 ; month:08 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.drugalcdep.2020.108116 |
|---|
| Katalog-ID: |
ELV050845284 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV050845284 | ||
| 003 | DE-627 | ||
| 005 | 20230624170328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200722s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drugalcdep.2020.108116 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica |
| 035 | |a (DE-627)ELV050845284 | ||
| 035 | |a (ELSEVIER)S0376-8716(20)30281-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.38 |2 bkl | ||
| 084 | |a 44.39 |2 bkl | ||
| 100 | 1 | |a Severe, Brooke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention |
| 264 | 1 | |c 2020 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention. | ||
| 650 | 7 | |a Opioid treatment program |2 Elsevier | |
| 650 | 7 | |a Treatment |2 Elsevier | |
| 650 | 7 | |a Models of care |2 Elsevier | |
| 650 | 7 | |a HCV |2 Elsevier | |
| 650 | 7 | |a Hepatitis C |2 Elsevier | |
| 650 | 7 | |a Opioid use disorder |2 Elsevier | |
| 650 | 7 | |a Retention |2 Elsevier | |
| 650 | 7 | |a OUD |2 Elsevier | |
| 700 | 1 | |a Tetrault, Jeanette M. |4 oth | |
| 700 | 1 | |a Madden, Lynn |4 oth | |
| 700 | 1 | |a Heimer, Robert |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Clark, Matthew ELSEVIER |t Statistical analysis to identify biomarkers for safety |d 2018 |d an international journal on biomedical and psychosocial approaches |g Amsterdam [u.a.] |w (DE-627)ELV000553670 |
| 773 | 1 | 8 | |g volume:213 |g year:2020 |g day:1 |g month:08 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.drugalcdep.2020.108116 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.38 |j Pharmakologie |q VZ |
| 936 | b | k | |a 44.39 |j Toxikologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 213 |j 2020 |b 1 |c 0801 |h 0 | ||
| author_variant |
b s bs |
|---|---|
| matchkey_str |
severebrooketetraultjeanettemmaddenlynnh:2020----:ooaehpttsvrsnetotetetihnnpodramnpormrmts |
| hierarchy_sort_str |
2020 |
| bklnumber |
44.38 44.39 |
| publishDate |
2020 |
| allfields |
10.1016/j.drugalcdep.2020.108116 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050845284 (ELSEVIER)S0376-8716(20)30281-7 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Severe, Brooke verfasserin aut Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention. Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD Elsevier Tetrault, Jeanette M. oth Madden, Lynn oth Heimer, Robert oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:213 year:2020 day:1 month:08 pages:0 https://doi.org/10.1016/j.drugalcdep.2020.108116 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 213 2020 1 0801 0 |
| spelling |
10.1016/j.drugalcdep.2020.108116 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050845284 (ELSEVIER)S0376-8716(20)30281-7 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Severe, Brooke verfasserin aut Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention. Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD Elsevier Tetrault, Jeanette M. oth Madden, Lynn oth Heimer, Robert oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:213 year:2020 day:1 month:08 pages:0 https://doi.org/10.1016/j.drugalcdep.2020.108116 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 213 2020 1 0801 0 |
| allfields_unstemmed |
10.1016/j.drugalcdep.2020.108116 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050845284 (ELSEVIER)S0376-8716(20)30281-7 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Severe, Brooke verfasserin aut Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention. Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD Elsevier Tetrault, Jeanette M. oth Madden, Lynn oth Heimer, Robert oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:213 year:2020 day:1 month:08 pages:0 https://doi.org/10.1016/j.drugalcdep.2020.108116 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 213 2020 1 0801 0 |
| allfieldsGer |
10.1016/j.drugalcdep.2020.108116 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050845284 (ELSEVIER)S0376-8716(20)30281-7 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Severe, Brooke verfasserin aut Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention. Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD Elsevier Tetrault, Jeanette M. oth Madden, Lynn oth Heimer, Robert oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:213 year:2020 day:1 month:08 pages:0 https://doi.org/10.1016/j.drugalcdep.2020.108116 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 213 2020 1 0801 0 |
| allfieldsSound |
10.1016/j.drugalcdep.2020.108116 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050845284 (ELSEVIER)S0376-8716(20)30281-7 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Severe, Brooke verfasserin aut Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention 2020 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention. Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD Elsevier Tetrault, Jeanette M. oth Madden, Lynn oth Heimer, Robert oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:213 year:2020 day:1 month:08 pages:0 https://doi.org/10.1016/j.drugalcdep.2020.108116 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 213 2020 1 0801 0 |
| language |
English |
| source |
Enthalten in Statistical analysis to identify biomarkers for safety Amsterdam [u.a.] volume:213 year:2020 day:1 month:08 pages:0 |
| sourceStr |
Enthalten in Statistical analysis to identify biomarkers for safety Amsterdam [u.a.] volume:213 year:2020 day:1 month:08 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Pharmakologie Toxikologie |
| institution |
findex.gbv.de |
| topic_facet |
Opioid treatment program Treatment Models of care HCV Hepatitis C Opioid use disorder Retention OUD |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Statistical analysis to identify biomarkers for safety |
| authorswithroles_txt_mv |
Severe, Brooke @@aut@@ Tetrault, Jeanette M. @@oth@@ Madden, Lynn @@oth@@ Heimer, Robert @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000553670 |
| dewey-sort |
3610 |
| id |
ELV050845284 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050845284</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624170328.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200722s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drugalcdep.2020.108116</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050845284</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0376-8716(20)30281-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.39</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Severe, Brooke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Opioid treatment program</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Models of care</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HCV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatitis C</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Opioid use disorder</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Retention</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OUD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tetrault, Jeanette M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Madden, Lynn</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heimer, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Clark, Matthew ELSEVIER</subfield><subfield code="t">Statistical analysis to identify biomarkers for safety</subfield><subfield code="d">2018</subfield><subfield code="d">an international journal on biomedical and psychosocial approaches</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000553670</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:213</subfield><subfield code="g">year:2020</subfield><subfield code="g">day:1</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drugalcdep.2020.108116</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="j">Pharmakologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.39</subfield><subfield code="j">Toxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">213</subfield><subfield code="j">2020</subfield><subfield code="b">1</subfield><subfield code="c">0801</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Severe, Brooke |
| spellingShingle |
Severe, Brooke ddc 610 ssgn 15,3 fid PHARM bkl 44.38 bkl 44.39 Elsevier Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention |
| authorStr |
Severe, Brooke |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000553670 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD Elsevier |
| topic |
ddc 610 ssgn 15,3 fid PHARM bkl 44.38 bkl 44.39 Elsevier Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD |
| topic_unstemmed |
ddc 610 ssgn 15,3 fid PHARM bkl 44.38 bkl 44.39 Elsevier Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD |
| topic_browse |
ddc 610 ssgn 15,3 fid PHARM bkl 44.38 bkl 44.39 Elsevier Opioid treatment program Elsevier Treatment Elsevier Models of care Elsevier HCV Elsevier Hepatitis C Elsevier Opioid use disorder Elsevier Retention Elsevier OUD |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j m t jm jmt l m lm r h rh |
| hierarchy_parent_title |
Statistical analysis to identify biomarkers for safety |
| hierarchy_parent_id |
ELV000553670 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Statistical analysis to identify biomarkers for safety |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000553670 |
| title |
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention |
| ctrlnum |
(DE-627)ELV050845284 (ELSEVIER)S0376-8716(20)30281-7 |
| title_full |
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention |
| author_sort |
Severe, Brooke |
| journal |
Statistical analysis to identify biomarkers for safety |
| journalStr |
Statistical analysis to identify biomarkers for safety |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Severe, Brooke |
| container_volume |
213 |
| class |
610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Severe, Brooke |
| doi_str_mv |
10.1016/j.drugalcdep.2020.108116 |
| dewey-full |
610 |
| title_sort |
co-located hepatitis c virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention |
| title_auth |
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention |
| abstract |
• Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention. |
| abstractGer |
• Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention. |
| abstract_unstemmed |
• Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA |
| title_short |
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention |
| url |
https://doi.org/10.1016/j.drugalcdep.2020.108116 |
| remote_bool |
true |
| author2 |
Tetrault, Jeanette M. Madden, Lynn Heimer, Robert |
| author2Str |
Tetrault, Jeanette M. Madden, Lynn Heimer, Robert |
| ppnlink |
ELV000553670 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.drugalcdep.2020.108116 |
| up_date |
2024-07-06T18:37:49.661Z |
| _version_ |
1803855928661901312 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050845284</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624170328.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200722s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drugalcdep.2020.108116</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050845284</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0376-8716(20)30281-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.39</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Severe, Brooke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Opioid treatment programs (OTP) can co-locate hepatitis C virus (HCV) treatment. • HCV treatment within an OTP is associated with improved opioid treatment retention.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Opioid treatment program</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Models of care</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HCV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatitis C</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Opioid use disorder</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Retention</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OUD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tetrault, Jeanette M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Madden, Lynn</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heimer, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Clark, Matthew ELSEVIER</subfield><subfield code="t">Statistical analysis to identify biomarkers for safety</subfield><subfield code="d">2018</subfield><subfield code="d">an international journal on biomedical and psychosocial approaches</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000553670</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:213</subfield><subfield code="g">year:2020</subfield><subfield code="g">day:1</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drugalcdep.2020.108116</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="j">Pharmakologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.39</subfield><subfield code="j">Toxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">213</subfield><subfield code="j">2020</subfield><subfield code="b">1</subfield><subfield code="c">0801</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4008465 |